NCT03616223View on ClinicalTrials.gov

FX-322 in Sensorineural Hearing Loss

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 3, 2018

Primary Completion Date

December 18, 2018

Study Completion Date

December 18, 2018

Conditions
Sensorineural Hearing Loss
Interventions
DRUG

FX-322

Intratympanic injection of FX-322 consists of laduviglusib and sodium valproate

DRUG

Placebo

Intratympanic injection

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

Sponsors
All Listed Sponsors
lead

Frequency Therapeutics

INDUSTRY